Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue The Lancet Haematology Année : 2017

Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial

Francoise Kraeber-Bodere
  • Fonction : Auteur
Loïc Campion
  • Fonction : Auteur
  • PersonId : 982002
Anne Moreau
  • Fonction : Auteur
  • PersonId : 913458
Isabelle Soubeyran
Steven Le Gouill
  • Fonction : Auteur
  • PersonId : 892875
Emmanuel Gyan
Sophie Sadot
  • Fonction : Auteur
Philippe Moreau
  • Fonction : Auteur
  • PersonId : 842727
Caroline Bodet-Milin
  • Fonction : Auteur
  • PersonId : 938697

Résumé

Radioimmunotherapy represents a potential option as consolidation after chemoimmunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantation. We aimed to assess activity and toxicity of fractionated radioimmunotherapy using anti-CD22 90Y-epratuzumab tetraxetan as consolidation after front-line induction chemoimmunotherapy in untreated elderly patients with diffuse large B-cell lymphoma.
Fichier non déposé

Dates et versions

hal-02425339 , version 1 (30-12-2019)

Identifiants

Citer

Francoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, Loïc Campion, Anne Moreau, et al.. Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. The Lancet Haematology, 2017, 4 (1), pp.e35-e45. ⟨10.1016/S2352-3026(16)30168-5⟩. ⟨hal-02425339⟩
491 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More